These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

900 related items for PubMed ID: 30646124

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT.
    JAMA Netw Open; 2018 Dec 07; 1(8):e186125. PubMed ID: 30646315
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM, Buse JB, Lund JL, Pate V, Stürmer T.
    Diabetes Obes Metab; 2018 Jan 07; 20(1):129-140. PubMed ID: 28661561
    [Abstract] [Full Text] [Related]

  • 10. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
    Zhang Y, Hong J, Chi J, Gu W, Ning G, Wang W.
    Diabetes Metab Res Rev; 2014 Mar 07; 30(3):241-56. PubMed ID: 24123720
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A, Rastogi M, Dhankhar P, Bell KF.
    J Med Econ; 2018 May 07; 21(5):497-509. PubMed ID: 29376760
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS, Steinke DT, Rutter MK, Emsley RA, Ashcroft DM.
    Diabetes Obes Metab; 2016 Sep 07; 18(9):916-24. PubMed ID: 27177784
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease.
    Jang H, Kim Y, Lee DH, Joo SK, Koo BK, Lim S, Lee W, Kim W.
    JAMA Intern Med; 2024 Apr 01; 184(4):375-383. PubMed ID: 38345802
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
    Heintjes EM, Overbeek JA, Hall GC, Prieto-Alhambra D, Lapi F, Hammar N, Bezemer ID.
    Clin Ther; 2017 Nov 01; 39(11):2296-2310.e14. PubMed ID: 29108837
    [Abstract] [Full Text] [Related]

  • 20. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
    Bachmann KN, Roumie CL, Wiese AD, Grijalva CG, Buse JB, Bradford R, Zalimeni EO, Knoepp P, Dard S, Morris HL, Donahoo WT, Fanous N, Fonseca V, Katalenich B, Choi S, Louzao D, O'Brien E, Cook MM, Rothman RL, Chakkalakal RJ.
    Pharmacol Res Perspect; 2020 Oct 01; 8(5):e00637. PubMed ID: 32881317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.